How do molecular aberrations guide therapy in MDS?

Rafael Bejar

doi:10.1016/j.beha.2021.101324

How do molecular aberrations guide therapy in MDS?

Best Pract Res Clin Haematol. 2021 Dec;34(4):101324. doi: 10.1016/j.beha.2021.101324. Epub 2021 Oct 23.

Author

Rafael Bejar¹

Affiliation

¹ UC San Diego Moores Cancer Center, 3855 Health Sciences Drive, San Diego, CA, 92093, USA. Electronic address: rabejar@ucsd.edu.

PMID: 34865696
DOI: 10.1016/j.beha.2021.101324

Abstract

Myelodysplastic syndromes (MDS) represent a cluster of genetically and phenotypically heterogeneous hematological disorders. While molecularly targeted therapies have entered the standard of care for other hematological malignancies like acute myeloid leukemia, this approach has been elusive in MDS. This review has summarized recent evidence to determine how molecular aberrations can be used to guide therapy in MDS and improve outcomes among patients.

Keywords: HMAs; Hypomethylating agents; Lenalidomide; MDS; Myelodysplastic syndromes; SF3B1; Splicing factor 3b subunit 1; TET2; TP53; Ten-eleven translocation-2.

Publication types

Review

MeSH terms

Humans
Leukemia, Myeloid, Acute* / genetics
Leukemia, Myeloid, Acute* / therapy
Molecular Targeted Therapy
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / therapy